FREMONT, Calif.--(BUSINESS WIRE)--DiscoveRx Corporation today announced the availability of an industry leading platform for studying Bromodomains, an emerging class of epigenetic targets. The new platform designated as BROMOscan™, is based on the proven KINOMEscan™ technology and will enable high throughput screening, selectivity profiling and quantitative Kd determinations across several sub-families of bromodomains, including the BET family.
